Browsing by Title

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:
 

Showing results 34116 to 34135 of 210609 < previous   next >
WHA3.50_eng.pdf.jpg
Continuing needs of children
World Health Assembly, 3 ( 1950 )
EB7R60_eng.pdf.jpg
Continuing needs of children and relations with UNICEF
Executive Board, 7 ( 1951 )
Continuing progress in the priority health areas: actions for Member States and WHO
Alwan, Ala ( 2014-11-01 )
EMHJ_2014_20_11_679_680.pdf.jpg
Continuing progress in the priority health areas:actions for Member States and WHO
Alwan, Ala ( 2014 )
Continuing the education of health workers : a workshop manual / F. R. Abbatt, A. Mej'ia
Abbatt, Fred R; Mej'ia, Alfonso; World Health Organization ( 1988 )
Abstract

A learning package designed to help decision-makers and planners develop a well-conceived system for continuing the education of health workers. Recognizing the need to stimulate broad-based interest and support, the book advocates use of a workshop, attended by policy-makers and people with influence in the health care system, as a starting point for the assessment of needs and formulation of plans. To this end, the book doubles as an introduction to the components of effective continuing education and a practical, how-to manual for organizing and conducting a workshop. The first nine chapters take readers through the range of problems and questions involved in identifying the needs for continuing education, developing a realistic plan for meeting these needs, implementing the plan, and then evaluating its results. The second part proposes a model timetable and schedule of topics for a five-day workshop, including 12 suggested exercises to be performed by participants. The final part offers practical tips on the day-to-day running of the workshop. Throughout the book, numerous practical examples, sample questions, check-lists, and tests serve to help readers think in terms of real situations, real problems, and realistic solutions

WHO_EMP_2009.1_eng.pdf.jpg
Continuity and change: implementing the third WHO Medicines Strategy 2008-2013
World Health Organization ( 2009 )
WPR_RC002_Res14_1951_en.pdf.jpg
Continuity of delegations to meetings of the World Health Organization (Resolution)
Regional Committee for the Western Pacific, 002 ( 1951 )
WPR_RC002_Res14_1951_en.pdf.jpg
Continuity of delegations to meetings of the World Health Organization (Resolution)
( 1951 )
Continuous isoniazid for the treatment of latent tuberculosis infection in people living with HIV
Matteelli, Alberto; Den Boon, Saskia; Ford, Nathan; Getahun, Haileyesus ( 2016-01-04 )
Abstract

This systematic review was carried out to determine the effectiveness of continuous isoniazid (given for at least 36 months) for the treatment of latent tuberculosis infection (LTBI) in people living with HIV (PLHIV).Six databases and HIV and tuberculosis (TB) conference abstract books were searched for randomized controlled trials that compared the effectiveness of continuous isoniazid with 6 months of isoniazid. Outcomes of interest were TB incidence, mortality, adverse events and risk of drug resistance. Data were pooled using fixed-effects meta-analysis.Three studies were included, from Botswana, South Africa and India. The risk of active TB was 38% lower among patients receiving continuous isoniazid compared with isoniazid regimen for 6 months [relative risk (RR) 0.62, 95% confidence interval (CI): 0.42-0.89; I = 0%], and 49% lower for those with a positive tuberculin skin test (TST) (RR 0.51, 95% CI: 0.30-0.86; I = 7%). Similarly, individuals with positive TST had a 50% lower chance of death (RR 0.50, 95% CI: 0.27-0.91; I = 3%). Two studies found no evidence of an increase in adverse events in the continuous isoniazid group, whereas a third study, that used a different definition for adverse events, found strong evidence of increase. There was no evidence of increased drug resistance when continuous isoniazid was given.For PLHIV in settings with high TB and HIV prevalence and transmission, continuous isoniazid for at least 36 months is beneficial and probably outweighs the risk of increased adverse events compared with an isoniazid regimen for 6 months.

9290612223_eng.pdf.jpg
The continuum of care for people living with HIV/AIDS in Cambodia : linkages and strengthening in the public health system : case study
World Health Organization. Regional Office for the Western Pacific ( 2006 )
Contra el tabaco, un idioma que los j'ovenes entienden / Jules Older
Older, Jules ( 1986 )
EB71_R13_spa.pdf.jpg
Contracción de personal internacional en la OMS
Consejo Ejecutivo, 71 ( 1983 )
WHO_TRS_619_spa.pdf.jpg
Contracepci'on por esteroides y riesgo de neoplasia : informe de un Grupo Cient'ifico de la OMS [se reuni'o en Ginebra del 5 al 9 de diciembre de 1977]
WHO Scientific Group on Steroid Contraception and the Risk of Neoplasia; World Health Organization ( 1978 )
Le contraceptif de la nature / Iqbal Shah et Jitendra Khanna
Shah, Iqbal H; Khanna, Jitendra ( 1987 )
WHO-RHR-17.04-fre.pdf.jpg
Contraceptifs hormonaux appropriés chez les femmes à risque élevé d’infection par le VIH : manuel d'orientation : recommandations concernant l'utilisation de méthodes contraceptives hormonales par les femmes exposées à un risque élevé d'infection par le VIH
Organisation mondiale de la Santé ( 2017 )
WHO_OFFSET_65_fre.pdf.jpg
Les Contraceptifs hormonaux injectables : aspects techniques et considérations de sécurité
World Health Organization ( 1982 )
Les Contraceptifs injectables : leur rôle en planification familiale
World Health Organization ( 1990 )
Abstract

Cet ouvrage présente des directives complètes à l'intention des responsables de programmes de planification familiale qui envisageraient d'introduire ou de répandre l'usage des contraceptifs injectables chez les femmes souhaitant une contraception. Cet ouvrage, qui s'appuie largement sur la recherche et l'expérience pratique, donne des informations et des conseils qui aideront les responsables de services à comprendre ce que la décision d'offrir des contraceptifs injectables implique en ce qui concerne tant le personnel et les services que la santé et le bien être des utilisatrices. L'accent est mis sur la sécurité et l'efficacité d'emploi de l'acétate de médroxyprogestérone retard (AMPR) et de l'énantate de noréthistérone (EN-NET), les deux produits contraceptifs injectables les plus couramment utilisés et dont la distribution est actuellement autorisée dans plus de 100 pays. Etant donné le risque de transmission du VIH par injections, cet ouvrage fournit des instructions précises sur la stérilisation des aiguilles et des seringues, la façon d'administrer correctement les injections, l'emploi sans danger d'aiguilles et de seringues jetables et les mesures à prendre pour éviter les erreurs dangereuses. Une série de cinq annexes apporte d'autres informations pratiques sur les pays et territoires dans lesquels l'AMPR et l'EN-NET sont homologués, les sources internationales d'assistance technique et de financement, les principaux fabricants de contraceptifs injectables, avec leur nom et leur adresse, la façon de calculer le niveau d'équilibre par rapport au nombre d'utilisatrices, et la liste des indicateurs pour l'évaluation des services distribuant des contraceptifs injectables

Les Contraceptifs oraux : aspects techniques et considérations de sécurité
World Health Organization ( 1982 )
Contraception and mechanisms of endometrial bleeding : proceedings of a symposium, Geneva, 28 November-2 December 1988 / edited by C. d' Arcangues ... [et al.]
D'Arcangues, Catherine; Fraser, I. S; Newton, J. R; Odlind, V; WHO Special Programme of Research, Development and Research Training in Human Reproduction ( 1990 )
10_3_2004_260_267.pdf.jpg
Contraception continuation rates and reasons for discontinuation in Zahedan, Islamic Republic of Iran
Rakhshani, F.; Mohammadi, M. ( 2004 )
Abstract

We evaluated contraception continuation rates and discontinuation reasons in Zahedan among 1741 women from 1998-2000. By Kaplan-Meier technique continuation rates were 92% for low dose combined hormonal oral contraceptives [OC], 86% for a levonorgestrel-releasing implant, 82% for intrauterine devices [IUD] and 53% for medroxyprogesterone acetate at the first year. After 3 years, continuation was 78% for levonorgestrel implant, 70% for OC, 60% for IUD and 44% for medroxyprogesterone acetate. The commonest reason for discontinuing OC and medroxyprogesterone acetate was changing method; for IUD and levonorgestrel-releasing implant, the commonest reason was side-effects. By Cox regression model, continuation rate and contraceptive type were significantly related to health centre

Showing results 34116 to 34135 of 210609 < previous   next >